Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• KRAS is a frequently mutated oncogene in non-small cell lung cancer (NSCLC).
• Targeted KRAS inhibitors are emerging, increasing interest in understanding KRAS mutation subtypes.
• Different KRAS mutations may influence prognosis and treatment response.

Purpose of the Study:

• To characterize the genomic landscape of advanced KRAS-mutated NSCLC.
• To identify co-occurring alterations, tumor mutational burden (TMB), and PD-L1 expression across KRAS mutation subtypes.
• To guide future therapeutic development for KRAS-mutated NSCLC.

Main Methods:

• DNA next-generation sequencing of 592 genes was performed on 17,095 NSCLC specimens.
• Specimens were classified based on KRAS mutation presence and subtype.
• Analysis included co-occurring genomic alterations, TMB, and PD-L1 expression (22C3, TPS).

Main Results:

• KRAS mutations were found in 27.5% of NSCLC cases, with G12C (40%), G12V (19%), and G12D (15%) being most common.
• KRAS G12C was associated with higher PD-L1 positivity (65.5%) and high PD-L1 expression (41.3%).
• STK11 mutations were more frequent in KRAS-mutant NSCLC, particularly G13 (36.2%), while TP53 mutations were more common in KRAS wild-type NSCLC (73.6%).

Conclusions:

• KRAS mutation subtypes exhibit distinct co-occurring mutations and genomic landscapes.
• These genomic differences may have clinical relevance for specific therapeutic interventions.
• Further investigation is warranted to explore the clinical utility of these findings.